mebikar has been researched along with ANS (Autonomic Nervous System) Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chutko, LS; Frolova, NI; Surushkina, SY | 1 |
| Chutko, LS; Kornishina, TL; Surushkina, SIu | 1 |
| Marchenko, AA; Puliatkina, OV; Samartsev, IN; Zhivolupov, SA | 1 |
3 trial(s) available for mebikar and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
[Psychoautonomic disorders in patients with hypertension, stage I and possibilities of their treatment].
Topics: Adult; Anti-Anxiety Agents; Anxiety; Autonomic Nervous System Diseases; Biureas; Female; Humans; Hypertension; Male; Middle Aged | 2013 |
[The use of adaptol in the treatment of the autonomic dystonia syndrome in children].
Topics: Autonomic Nervous System Diseases; Biureas; Child; Dystonic Disorders; Female; Humans; Male; Treatment Outcome | 2011 |
[The prognostic significance of brain-derived neurotrophic factor (BDNF) for phobic anxiety disorders, vegetative and cognitive impairments during conservative treatment including adaptol of some functional and organic diseases of nervous system].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Autonomic Nervous System Diseases; Biureas; Brain-Derived Neurotrophic Factor; Cognition Disorders; Dose-Response Relationship, Drug; Humans; Middle Aged; Phobic Disorders; Prognosis; Treatment Outcome; Young Adult | 2012 |